血友病及其他出血性疾病的新型治疗药物
血友病和血管性血友病是最常见的先天性出血性疾病,传统治疗以补充缺失的凝血因子为主。新兴旁路药物、双特异性抗体艾米珠单抗、组织因子途径抑制物及蛋白C/S系统等靶点药物、修饰型因子VIII分子以及首个重组血管性血友病因子产品正在开发或已获批,可能提供更好的给药途径、改善的剂量方案和更优的出血防治疗效。
要点
- 艾米珠单抗在伴抑制物的A型血友病患者3期试验中显示疗效。
- 首个重组血管性血友病因子产品已获批,不含因子VIII且多聚体组成独特。
- 新兴旁路药物包括酶原型因子IXa和Xa分子,正在开发中。
核心结论
- 这些新方法可能为先天性出血性疾病的出血预防和治疗提供更好的给药途径、改善的剂量方案和更优的疗效。
主要发现
- 艾米珠单抗在伴抑制物的A型血友病患者3期试验中显示疗效。
- 首个重组血管性血友病因子产品已获批,具有独特的血管性血友病因子多聚体组成且不含因子VIII。
- 新兴旁路药物包括酶原型因子IXa和Xa分子,正在开发中。
- 组织因子途径抑制物、蛋白C/S系统和抗凝血酶是正在开发的新型化合物的靶点,用以改变止血平衡。
- 使用修饰型因子VIII分子的新方法正在A型血友病中测试用于预防和清除抑制物抗体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia and von Willebrand disease are the most common congenital bleeding disorders. Treatment of these disorders has focused on replacement of the missing coagulation factor to prevent or treat bleeding. New technologies and insights into hemostasis have driven the development of many promising new therapies for hemophilia and von Willebrand disease. Emerging bypass agents including zymogen-like factor IXa and Xa molecules are in development and a bispecific antibody, emicizumab, demonstrated efficacy in a phase 3 trial in people with hemophilia A and inhibitors. Tissue factor pathway inhibitor, the protein C/S system, and antithrombin are targets of novel compounds in development to alter the hemostatic balance and new approaches using modified factor VIII molecules are being tested for prevention and eradication of inhibitor antibodies in hemophilia A. The first recombinant von Willebrand factor (VWF) product has been approved and has unique VWF multimer content and does not contain factor VIII. These new approaches may offer better routes of administration, improved dosing regimens, and better efficacy for prevention and treatment of bleeding in congenital bleeding disorders.
引用
- Callaghan MU, Sidonio R, Pipe SW, et al. Novel therapeutics for hemophilia and other bleeding disorders. Blood. 2018. PMID: 29769259. doi:10.1182/blood-2017-09-743385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。